Max Planck Innovation
Max-Planck-Innovation GmbH is the wholly-owned technology transfer organization of the Max Planck Society, managing its patent portfolio, executing ~80 new license agreements annually, and supporting deep-tech spin-offs across life sciences, materials, microscopy, photonics, quantum, and fusion for global industrial partners and investors.
- Company typePrivate
- Founded1970
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Max Planck Innovation does
Max-Planck-Innovation GmbH is the wholly-owned technology transfer organization of the Max-Planck-Gesellschaft (Max Planck Society), Germany's largest publicly funded basic research body. Headquartered in Munich since 1970, the company serves as the exclusive commercial interface for IP emanating from 80+ Max Planck Institutes, which collectively publish more than 15,000 scientific contributions per year. Its mandate is to convert basic research into economic and societal utility through three core service lines: Patent & License Management (invention evaluation, patent filing, and license negotiation), Start-up Management (from initial spin-off ideation through business plan, fundraising, and company founding), and a diversified Technology Offerings portfolio spanning 13 categories including analytics, IT/software, life sciences, microscopy, photonics, quantum technologies, and fusion energy.
Operationally, Max Planck Innovation runs two flagship programs that sit on top of the core services: the MAX!mize incubator, which delivers individualized curriculum, mentorship, and networking to MPG researchers, and the Prove2Move validation program, launched in 2026 with an annual €4M budget to de-risk early-stage technologies that are otherwise too immature for licensees or investors. The business model is multi-stream: revenue is generated through licensing royalties (one-time fees, milestone payments, revenue shares, and annual minimum royalties on the ~2,800 exploitation contracts concluded to date and ~80 new agreements signed annually), equity stakes retained in spin-offs (e.g., QLi5, Batene, Meshcapade, Ovo Labs), and to a lesser extent event-driven investor matching (4Investors Day, BioVaria). Customers split into three segments — industrial licensees (pharma, biotech, microscopy, battery tech, and adjacent verticals), MPG researchers seeking commercialization support, and VC/family-office investors seeking deep-tech deal flow. Geographic reach spans Germany, broader Europe, the United States, and Japan.
Recent strategic activity underscores both the scale and the momentum of the model: MPG spin-offs launched 14 new startups in 2025 (nearly double the prior year), produced four unicorns with a combined capital valuation exceeding €67B, and achieved marquee exits such as Epic Games' acquisition of Meshcapade (with Max Planck Innovation retaining SMPL licensing rights). Strategic partners include Bayer, Leica Microsystems, Alnylam Pharmaceuticals, Gelion PLC, the Lead Discovery Center, SPRIND, and the Schwarz Gruppe. The organization is privately held and does not disclose revenue; its growth is measured primarily through portfolio throughput, spin-off formation, license deal volume, and the equity value created in portfolio companies rather than top-line figures.
Max Planck Innovation firmographics
Firmographics- Name
- Max Planck Innovation
- Legal name
- Max-Planck-Innovation GmbH
- Website
- https://max-planck-innovation.de
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Max-Planck-Innovation GmbH is the wholly-owned technology transfer organization of the Max Planck Society, managing its patent portfolio, executing ~80 new license agreements annually, and supporting deep-tech spin-offs across life sciences, materials, microscopy, photonics, quantum, and fusion for global industrial partners and investors.
- Ownership category
- akta.pro rank
Max Planck Innovation industry classification
Industry- Product category
- Technology Transfer Services
- NAICS
- Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (541)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Engineering Services (8711)
- akta.pro primary industry
- Standards-Essential Patents (SEP) & FRAND Advisory (BPAHAMAL)
Keywords
Where Max Planck Innovation is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Max Planck Innovation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Patent and Technology Licensing: Max Planck Innovation generates revenue through licensing agreements with industrial partners for patented technologies and know-how. Approximately 80 new license agreements are signed each year, and roughly 2,800 exploitation contracts have been concluded to date. License structures include one-time payments, revenue shares, milestone payments (e.g., in drug development), and annual minimum royalties.
- Equity Stakes in Spin-offs: Max Planck Innovation holds equity stakes in spin-off companies founded from Max Planck research (e.g., QLi5, Batene, Meshcapade, Ovo Labs). Returns on these equity positions contribute to revenue and reflect successful commercialization of MPG IP.
Go-to-market motion4 records
Distribution channels3 records
Marketing channels7 records
Max Planck Innovation product offering
Product offeringCore offering
Max-Planck-Innovation GmbH is the central technology transfer organization for the Max Planck Society (MPG). It evaluates inventions from 80+ Max Planck Institutes, files and prosecutes patents, negotiates license agreements with industrial partners across pharma, biotech, microscopy, materials, photonics, quantum tech, and fusion energy, and supports Max Planck researchers in founding spin-off companies. It operates the MAX!mize startup incubator and the Prove2Move €4M/year validation program, currently managing roughly 2,800 cumulative exploitation contracts with about 80 new license agreements signed each year.
Product overview
Max Planck Innovation is the technology transfer organization for the Max Planck Society, responsible for managing patents, licenses, and spin-offs from Max Planck research institutes. The organization operates as a service provider rather than a product company, offering three core services: Patent & License Management (advisory on evaluating and patenting research results, plus license negotiation), Start-up Management (comprehensive consulting for spin-offs from business plan through fundraising), and a portfolio of Technology Offerings (patents and know-how available for licensing across diverse categories). Key programs include the MAX!mize Start-up Incubator Program providing tailored incubation for researchers, and the Prove2Move Validation Program with annual funding of four million euros. The technology offerings portfolio spans multiple domains including life sciences, materials science, photonics, quantum technologies, and fusion technology, with specific technologies highlighted such as an ultrarapid cryo-fixation microscopy module, nanographene-based dyes for super-resolution microscopy, nanoporous polymer films, an ultracompact medical ventilation system, RNA-based therapeutics platforms, and various diagnostic and analytical technologies.
Differentiator
Problem solved
Functional benefit
Brands
- MAX!mize: Startup incubation program for Max Planck researchers providing individual support, customized curriculum, and networking opportunities to transfer founding ideas into successful startups.
Products and services
- Patent & License Management Advisory services for Max Planck researchers on evaluating and patenting research results, plus license contract negotiation support for both researchers and industrial partners. Includes invention disclosure assessment, patent filing decisions, and structuring of license agreements (upfront fees, milestones, royalties, annual minimums).
- Start-up Management Comprehensive consulting for Max Planck scientists from evaluating spin-off ventures through to fundraising support, including business plan development and startup incubation assistance. Covers initial consultations, business plan development, funding program guidance, fundraising support, and team-completion advice.
- Technology Offerings Portfolio (Lizenzierbare Technologieangebote) Portfolio of patents and know-how from Max Planck Institutes available for licensing, spanning 13 categories including Analytik, IT/Software/Bioinformatik, Medizin, Prozesse und Methoden, Forschungs-Reagenzien, Nukleinsäure/Protein/Zell-bezogene Technologien, Grüne Biotechnologie, Bildgebung und Mikroskopie, Neue Materialien, Sensoren/Geräte/Komponenten, Photonics, Quantentechnologien, and Fusionstechnologie/-energie. Represents ~80 new license agreements per year.
- MAX!mize Start-up Incubator Program Incubation program providing aspiring Max Planck researchers with individualized support, a tailored curriculum, and networking opportunities to transfer founding ideas into successful start-ups. Operates as a sub-brand of Max-Planck-Innovation.
- Prove2Move Validation Program Annual four-million-euro funding program designed to help Max Planck researchers validate early-stage technologies and reduce technological risks before commercialization. Addresses the gap where licensees and investors consider early-stage validation too risky; supports subsequent licensing or spin-off formation.
Quantifiable outcome
- Four unicorn spin-offs with combined capital valuation exceeding €67B, and a #2 ranking among European research organizations for deep tech and life science spin-offs
- +3 more outcomes
Companies that use Max Planck Innovation
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Max Planck Innovation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Max Planck Innovation partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- Gelion PLCcoreGelion PLC signed an exclusive commercial licence agreement with Max-Planck-Innovation GmbH securing long-term global rights to intellectual property covering nano-encapsulated sulfur cathode technology and novel nano-confined anode materials for sulfur batteries. The deal formalizes an option secured in March 2025 and includes staged cash payments and royalties over net sales.
- Lead Discovery Center (LDC)coreThe Lead Discovery Center (LDC) is a joint venture between the Max Planck Society and the Lead Discovery Center GmbH, co-founding spin-offs such as QLi5 Therapeutics together with Qurient and Nobel laureate Prof. Robert Huber. The LDC bridges the gap between academic research and the pharmaceutical industry in early drug discovery, and co-develops therapeutic approaches with MPG researchers.
- BioVaria (Main Partner)flagshipMax Planck Innovation is a main partner (alongside the Lead Discovery Center) of the BioVaria conference, an annual platform connecting life science innovations from research institutions with industry and investors. At BioVaria 2026, Max Planck Innovation presented four breakthrough technologies from MPG institutes in areas including RNA therapeutics, single-cell sequencing, and lung function diagnostics.
- BayercoreBayer has licensed MPG technology that led to the development of a new cancer treatment approach currently in Phase 1 clinical trial, through a cooperation between the Lead Discovery Center and Bayer HealthCare. Bayer's Senior Vice President for Global Drug Discovery cited Max Planck Innovation as providing excellent access to the technology portfolio of various Max Planck Institutes.
- Leica MicrosystemscoreLeica Microsystems licensed Nobel laureate Stefan Hell's STED and GSDIM super-resolution microscopy technologies from the Max Planck Institute for Biophysical Chemistry, resulting in products that set new standards in the life sciences and enabled discoveries in virology, neuroscience, and oncology.
- Alnylam PharmaceuticalscoreAlnylam Pharmaceuticals has maintained a long-standing IP partnership with Max Planck Innovation since 2002 for the development of RNAi therapeutics. Alnylam's CEO cited Max Planck Innovation as a strong partner in the development of RNAi therapeutics for the benefit of patients.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Max Planck Innovation competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Max Planck Innovation social profiles
Digital presenceMax Planck Innovation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Max Planck Innovation leadership team
Management profileNumber of profiles
Profiles10 records
Max Planck Innovation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Max Planck Innovation M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Max Planck Innovation
What does Max Planck Innovation do?
Max-Planck-Innovation GmbH is the central technology transfer organization for the Max Planck Society (MPG). It evaluates inventions from 80+ Max Planck Institutes, files and prosecutes patents, negotiates license agreements with industrial partners across pharma, biotech, microscopy, materials, photonics, quantum tech, and fusion energy, and supports Max Planck researchers in founding spin-off companies. It operates the MAX!mize startup incubator and the Prove2Move €4M/year validation program, currently managing roughly 2,800 cumulative exploitation contracts with about 80 new license agreements signed each year.
Is Max Planck Innovation a public or private company?
Max Planck Innovation is a private company. It is classified as corporate owned and is currently operating.
When was Max Planck Innovation founded?
Max Planck Innovation was founded in 1970. It employs 11 to 50 people.
Where is Max Planck Innovation based?
Max Planck Innovation is headquartered in Munich, Germany, in the Europe region.
How does Max Planck Innovation make money?
Two revenue lines are on record. Patent and Technology Licensing is the primary driver. The others are equity Stakes in Spin-offs.
Does Max Planck Innovation have an API?
No public API is recorded for Max Planck Innovation.
What industry is Max Planck Innovation in?
Max Planck Innovation's product category is Technology Transfer Services. Its primary akta.pro industry code is BPAHAMAL, Standards-Essential Patents (SEP) & FRAND Advisory. Its NAICS code is 5417 and its SIC code is 8731.